Literature DB >> 19619522

NAP protects against cytochrome c release: inhibition of the initiation of apoptosis.

Ilona Zemlyak1, Robert Sapolsky, Illana Gozes.   

Abstract

NAPVSIPQ (NAP), an 8 amino acid peptide derived from activity-dependent neuroprotective protein (ADNP), provides neuroprotection through interaction with microtubules. Previous results have demonstrated NAP protection against oxygen-glucose deprivation in hippocampal cells in culture. Furthermore, in vivo studies have shown that NAP reduces caspase 3 activation in rats subjected to permanent mid-cerebral artery occlusion (a rat model of stroke). Oxygen-glucose deprivation (ischemia) has been associated with microtubule breakdown and cytochrome c release from mitochondria leading to apoptosis. Here, NAP in concentrations ranging from 10(-14)M to 10(-8)M completely blocked cytochrome c release in cortical neurons subjected to oxygen-glucose deprivation. Furthermore, quantitative microscopy coupled to microtubule immunocytochemistry suggested that NAP prevented microtubule degradation under oxidative stress. As cytochrome c release is a known initiator of the apoptotic pathway, it is suggested that NAP inhibits the early events of apoptosis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19619522     DOI: 10.1016/j.ejphar.2009.07.013

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  18 in total

1.  Strategies to defeat ketamine-induced neonatal brain injury.

Authors:  C P Turner; S Gutierrez; C Liu; L Miller; J Chou; B Finucane; A Carnes; J Kim; E Shing; T Haddad; A Phillips
Journal:  Neuroscience       Date:  2012-02-23       Impact factor: 3.590

2.  Strategies for diminishing katanin-based loss of microtubules in tauopathic neurodegenerative diseases.

Authors:  Haruka Sudo; Peter W Baas
Journal:  Hum Mol Genet       Date:  2010-11-30       Impact factor: 6.150

Review 3.  Microtubule-Tau Interaction as a Therapeutic Target for Alzheimer's Disease.

Authors:  Yanina Ivashko Pachima; Liu-yao Zhou; Peng Lei; Illana Gozes
Journal:  J Mol Neurosci       Date:  2016-02       Impact factor: 3.444

4.  Davunetide (NAP) protects the retina against early diabetic injury by reducing apoptotic death.

Authors:  Soraya Scuderi; Agata Grazia D'Amico; Alessandro Castorina; Concetta Federico; Giuseppina Marrazzo; Filippo Drago; Claudio Bucolo; Velia D'Agata
Journal:  J Mol Neurosci       Date:  2014-02-02       Impact factor: 3.444

Review 5.  Mitochondrial dysfunction as a therapeutic target in progressive supranuclear palsy.

Authors:  Vincent Ries; Wolfgang H Oertel; Günter U Höglinger
Journal:  J Mol Neurosci       Date:  2011-07-27       Impact factor: 3.444

6.  Isoflurane enhances the expression of cytochrome C by facilitation of NMDA receptor in developing rat hippocampal neurons in vitro.

Authors:  Yilin Zhao; Xiaogao Jin; Jintao Wang; Lei Tan; Shiyong Li; Ailin Luo
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2011-12-16

7.  New horizons in schizophrenia treatment: autophagy protection is coupled with behavioral improvements in a mouse model of schizophrenia.

Authors:  Avia Merenlender-Wagner; Zeev Shemer; Olga Touloumi; Roza Lagoudaki; Eliezer Giladi; Annie Andrieux; Nikolaos C Grigoriadis; Illana Gozes
Journal:  Autophagy       Date:  2014       Impact factor: 16.016

8.  Protein profiling reveals antioxidant and signaling activities of NAP (Davunetide) in rodent hippocampus exposed to hypobaric hypoxia.

Authors:  Niroj Kumar Sethy; Narendra Kumar Sharma; Mainak Das; Kalpana Bhargava
Journal:  J Mol Neurosci       Date:  2014-07-20       Impact factor: 3.444

Review 9.  D-NAP prophylactic treatment in the SOD mutant mouse model of amyotrophic lateral sclerosis: review of discovery and treatment of tauopathy.

Authors:  Yan Jouroukhin; Regina Ostritsky; Illana Gozes
Journal:  J Mol Neurosci       Date:  2012-11       Impact factor: 3.444

10.  Tau pathology: predictive diagnostics, targeted preventive and personalized medicine and application of advanced research in medical practice.

Authors:  Illana Gozes
Journal:  EPMA J       Date:  2010-06-12       Impact factor: 6.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.